Special Edition

Special Edition

CPX-351 Outperforms Induction Chemotherapy in Older High-Risk Patients With AML

Older patients (≥60 years of age) with acute myeloid leukemia (AML) often have lower remission rates and increased induction mortality with intensive induction chemotherapy,...

Clinical Trial Updates

A look at ongoing clinical trials in myeloid malignanciesControlled Study of Rigosertib Versus Physician’s Choice of Treatment in MDS Patients After Failure of an...

The Myeloid Malignancies Pipeline

Below is a list of agents currently under investigation for the treatment of myeloid malignancies, including acute myeloid leukemia (AML), chronic myeloid leukemia (CML),...

Durable Response Observed With Pracinostat and Azacitidine for Older Patients With AML

The inhibition of both histone deacetylation (HDAC) and DNA hypermethylation induces re-expression of silenced genes in vitro in cell lines and in primary cells...

AML and Other Myeloid Neoplasms According to WHO A Look at the Revised Classification

In June 2016 the World Health Organization (WHO) updated its 2008 classification of tumors of the hematopoietic and lymphoid tissues. The revised myeloid disorders...

More Mutations, More Problems? Assessing Mutation Burden and Response to HMAs in MDS

Previous research has suggested that the presence of a TET2 mutation can predict which patients with myelodysplastic syndromes (MDS) are more likely to have...

SWOG S1203: Comparing Standards of Care for Acute Myeloid Leukemia

Investigators from the phase III US Intergroup SWOG-led S1203 trial reported that remission induction with 7+3 chemotherapy (cytarabine plus daunorubicin) should remain the standard...

Azacitidine and Donor Lymphocyte Infusions Reduce Risk of Relapse in Post-Transplant AML and MDS

Although allogeneic hematopoietic cell transplantation (alloHCT) is currently the only curative option for many patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS),...
stem cell

Optimizing Post-Transplant Outcomes for Patients With MDS

Two analyses from the European Society for Blood and Marrow Transplantation (EBMT) reported on post-allogeneic hematopoietic cell transplantation (alloHCT) among patients with myelodysplastic syndromes...

Nature of Prior Myeloid Neoplasm Influences Outcome of Secondary AML

In an analysis of data from the European Society of Blood and Marrow Transplantation (EBMT) registry, researchers found that patients with secondary (transformed) acute...
Advertisement

Current Issue

July 2019 Bonus Mid-Year Edition, Volume 5, Issue 9

This issue features a look at research espionage, coverage from the ASCO and EHA annual meetings, and more.